Gocovri™ (amantadine) – New drug approval
August 24, 2017 – Adamas announced the FDA approval of Gocovri (amantadine) extended-release capsules, for the treatment of dyskinesia in patients with Parkinson’s disease (PD) receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Top